CTLA4 and cancer: Previous pre-clinical studies using the TRAMP model revealed the efficacy of anti-CTLA4 therapy following the administration of an irradiated cell-based cancer vaccine in radiation-naïve cancer through the activation of effector T-cell response [55,56,57].